Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

BCYC
Bicycle Therapeutics plc
stock NASDAQ ADR

At Close
Jul 31, 2026 3:59:55 PM EDT
3.87USD-3.616%(-0.14)330,331
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 30, 2026 8:59:30 AM EDT
3.85USD-3.990%(-0.16)0
After-hours
Jul 31, 2026 4:08:30 PM EDT
3.84USD-0.608%(-0.02)21,723
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
07:10AM EST  Bicycle Therapeutics Announces Clinical Progress And Updates To Management Team; COO Michael Skynner Appointed To CTO Role   Benzinga
07:06AM EST  Bicycle Therapeutics Announces Continued Progress In Phase I/II Trials Of BT8009, BT5528 And BT7480   RTTNews
07:00AM EST  Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team   Business Wire
Dec 17, 2021
10:18AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021   Benzinga
06:24AM EST  SVB Leerink Initiates Coverage On Bicycle Therapeutics with Outperform Rating, Announces Price Target of $70   Benzinga
Dec 9, 2021
09:50PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021   Benzinga
09:44PM EST  Needham Initiates Coverage On Bicycle Therapeutics with Buy Rating, Announces Price Target of $85   Benzinga
Nov 11, 2021
07:00AM EST  Bicycle Therapeutics to Participate in Upcoming Investor Conferences   Business Wire
Nov 9, 2021
08:00AM EST  Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist(tm) (Bicycle TICA(tm)) Programs at the SITC 36th Annual Meeting   Business Wire
Nov 8, 2021
10:13AM EST  Looking Into Bicycle Therapeutics's Return On Capital Employed   Benzinga
Nov 4, 2021
07:22AM EDT  Bicycle Therapeutics Q3 EPS $(0.59) Down From $(0.52) YoY   Benzinga
07:15AM EDT  Bicycle Therapeutics Q3 Net Loss Widens To $14.7 Mln From $10.1 Mln Last Year   RTTNews
07:14AM EDT  Bicycle Therapeutics Announces First Patient Dosed In Phase I/II Trial Of Bicycle Tumor-targeted Immune Cell Agonist BT7480 In Patients With Advanced Solid Tumors Associated With Nectin-4 Expression   Benzinga
06:59AM EDT  Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
06:45AM EDT  Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle(r) Tumor-targeted Immune Cell Agonist(tm) BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression   Business Wire
Nov 2, 2021
10:50AM EDT  Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program In Journal For ImmunoTherapy Of Cancer   Benzinga
07:15AM EDT  Bicycle Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program On ImmunoTherapy Of Cancer   RTTNews
07:10AM EDT  Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer   Business Wire
Oct 26, 2021
08:11AM EDT  Bicycle Therapeutics Reports Expansion Of Its Genentech Immuno-Oncology Collab; Genentech Exercised Option To Include New Program Under Deal, Triggers $10M Payment To Bicycle   Benzinga
08:05AM EDT  Bicycle Therapeutics plc (BCYC) on Tuesday said Genentech, a member of the Roche Group, has expanded its 2020 collaboration agreement for Bicycle's proprietary bicyclic peptide technology (Bicycle)-based immuno-oncology therapies.   RTTNews
07:16AM EDT  Bicycle Therapeutics Announces Expansion Of Genentech Immuno-Oncology Collaboration   RTTNews
Oct 18, 2021
07:01AM EDT  Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
Oct 14, 2021
08:41AM EDT  JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Raises Price Target to $85   Benzinga
Oct 13, 2021
12:40AM EDT  Bicycle Therapeutics Announces Pricing Of Upsized Public Offering Of 3.24 Mln ADSs At $54/ADS   RTTNews
12:38AM EDT  Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares   Business Wire
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
07:10AM EDT  Bicycle Therapeutics Announces Proposed $125 Mln Public Offering Of ADSs   RTTNews
06:59AM EDT  Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares   Benzinga
Oct 8, 2021
06:52AM EDT  HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Raises Price Target to $65   Benzinga
Oct 7, 2021
03:16PM EDT  Bicycle Therapeutics Shares To Resume Trade At 3:20 p.m. EDT   Benzinga
12:52PM EDT  UPDATE: Bicycle Notes 'In the ongoing BT8009 Phase I trial in monotherapy cohorts, 4 out of 11 urothelial patients had partial responses; Phase I dose escalation remains ongoing, with no dose limiting toxicities (DLTs) yet observed'   Benzinga
12:52PM EDT  UPDATE: Bicycle Says 'A recommended BT5528 Phase II dose (RP2D) range has been established at 6.5-8.5mg/m2 every other week; expansion cohorts expected to initiate in 2022'   Benzinga
12:51PM EDT  UPDATE: Bicycle Reports 'BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed...'   Benzinga
12:51PM EDT  Bicycle Therapeutics Reports Interim Results From Phase 1 Trial OF BT5528   Benzinga
12:50PM EDT  Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial   Business Wire
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Sep 30, 2021
04:33PM EDT  Bicycle Therapeutics To Present BT5528 Interim Phase I Data At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics   Benzinga
11:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021   Benzinga
06:13AM EDT  B. Riley Securities Initiates Coverage On Bicycle Therapeutics with Buy Rating, Announces Price Target of $56   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 16, 2021
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 8, 2021
10:37AM EDT  Bicycle Therapeutics Earnings Perspective: Return On Capital Employed   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
07:00AM EDT  Bicycle Therapeutics to Participate in Upcoming Investor Conferences   Business Wire
Aug 5, 2021
07:22AM EDT  Bicycle Therapeutics Q2 Net Loss $17.9 Mln Vs Net Loss $12.1 Mln Last Year   RTTNews
07:14AM EDT  Bicycle Therapeutics Q2 EPS $(0.74) Down From $(0.67) YoY, Sales $1.78M Up From $1.57M YoY   Benzinga
06:59AM EDT  Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
Jul 15, 2021
10:38AM EDT  Canaccord Genuity Maintains Buy on Bicycle Therapeutics, Raises Price Target to $40   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 13, 2021
10:29AM EDT  Canaccord Genuity Maintains Buy on Bicycle Therapeutics, Raises Price Target to $36   Benzinga
08:06AM EDT  Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics   Benzinga
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
07:11AM EDT  Ionis Pharma Enters Deal With Bicycle Therapeutics To Increase Delivery Capabilities Of Ionis' Advanced LICA Medicines   RTTNews
07:00AM EDT  Bicycle Therapeutics Enters Exclusive License And Collaboration Agreement With Ionis To Develop Targeted Oligonucleotide Therapeutics; Bicycle To Receive $45M Upfront Payment And Is Eligible For Milestone Payments And Royalties   Benzinga
07:00AM EDT  Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at   PR Newswire
07:00AM EDT  Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics   Business Wire
Jun 15, 2021
04:30PM EDT  Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021   Business Wire
May 27, 2021
07:00AM EDT  Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
May 7, 2021
07:50AM EDT  HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Raises Price Target to $39   Benzinga
May 6, 2021
07:56AM EDT  Bicycle Therapeutics Q1 EPS $(0.73) Down From $(0.63) YoY, Sales $1.81M Up From $1.13M YoY   Benzinga
07:00AM EDT  Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
Apr 20, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021   Benzinga
06:44AM EDT  JMP Securities Initiates Coverage On Bicycle Therapeutics with Market Outperform Rating, Announces Price Target of $53   Benzinga
Apr 12, 2021
10:04AM EDT  Bicycle Therapeutics Announced Saturday Morning Presentation At American Association For Cancer Research Conference; BT7480 On-Track To Enter Clinic In 2H'21   Benzinga
Apr 10, 2021
08:30AM EDT  Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021   Business Wire
Apr 7, 2021
11:48AM EDT  Bicycle Therapeutics Development Partner Oxurion Highlights Publication In Progress In Retinal Eye Research Highlights THR-149   Benzinga
Mar 30, 2021
07:11AM EDT  Bicycle Therapeutics Announces Progress Updates For Bicycle-based Partnered Programs Outside Of Oncology   RTTNews
07:10AM EDT  Bicycle Therapeutics Highlights Progress Across Therapeutic Programs   Benzinga
07:00AM EDT  Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology   Business Wire
Mar 18, 2021
08:37AM EDT  Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos To Its Board   RTTNews
08:34AM EDT  Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors   Business Wire
Mar 11, 2021
04:05PM EST  Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference   Business Wire
07:23AM EST  Bicycle Therapeutics Q4 Net Loss $17.4 Mln Or $0.83/Shr Vs Loss Of $4.4 Mln Or $0.25/Shr Last Year   RTTNews
07:07AM EST  Bicycle Therapeutics Q4 EPS $(0.83) Down From $(0.25) YoY, Sales $3.85M Down From $5.28M YoY   Benzinga
07:00AM EST  Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update   Business Wire
Jan 26, 2021
07:22AM EST  Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs) in the Journal for ImmunoTherapy of Cancer   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
10:50AM EST  Bicycle Therapeutics shares were trading higher after HC Wainwright maintained a Buy rating and raised its price target from $28 to $31.   Benzinga
06:09AM EST  HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Raises Price Target to $31   Benzinga
Jan 14, 2021
10:32AM EST  Shares of Bicycle Therapeutics plc (BCYC) are surging more than 20% Thursday morning after the company announced its pipeline progress update for its early and mid-stage cancer trials.   RTTNews
07:13AM EST  Bicycle Therapeutics Says Start 2021 By Announcing Clinical Progress Across Internal Oncology Pipeline   RTTNews
07:04AM EST  Bicycle Therapeutics Announces Pipeline Progress Update   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Nov 24, 2020
06:59AM EST  Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare Conference   Business Wire
Nov 20, 2020
04:10PM EST  Bicycle Therapeutics Announces A Settlement For A Patent Dispute With Pepscan Systems B.V.   Benzinga
04:05PM EST  Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.   Business Wire
Nov 12, 2020
04:01PM EST  Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare Conference   Business Wire
Nov 9, 2020
06:59AM EST  Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting   Business Wire
Nov 5, 2020
07:52AM EST  Bicycle Therapeutics Q3 Net Loss $10.1 Mln Or $0.52/shr Vs Net Loss $9.5 Mln Or $0.53/shr Last Year   RTTNews
07:03AM EST  Bicycle Therapeutics Q3 EPS $(0.52) Up From $(0.53) YoY, Sales $3.84M Up From $614.00K YoY   Benzinga
06:59AM EST  Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update   Business Wire
Oct 21, 2020
06:59AM EDT  Bicycle Therapeutics Announces Expansion of Scientific Advisory Board   Business Wire
Oct 14, 2020
05:08PM EDT  Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting   Business Wire
Oct 12, 2020
12:39PM EDT  Cantor Fitzgerald Initiates Coverage On Bicycle Therapeutics with Overweight Rating, Announces Price Target of $30   Benzinga
Oct 1, 2020
08:09AM EDT  Bicycle Therapeutics Reports $50M From At-The-Market Offering Program, Enters $40M Debt Financing From Hercules Capital   Benzinga
08:06AM EDT  Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital   Business Wire
Sep 14, 2020
06:59AM EDT  Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020   Business Wire
Sep 10, 2020
04:08PM EDT  Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors   Benzinga
07:12AM EDT  Canaccord Genuity Maintains Buy on Bicycle Therapeutics, Raises Price Target to $25   Benzinga
Sep 3, 2020
06:59AM EDT  Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences   Business Wire
Sep 2, 2020
07:05AM EDT  Bicycle Therapeutics Says First Patient Dosed In Phase IIa Trial Of Bicycle Toxin Conjugate BT1718   RTTNews
06:59AM EDT  Bicycle Therapeutics Announces First Patient Dosed In Phase IIa Trial Of Bicycle Toxin Conjugate BT1718   Benzinga
Sep 1, 2020
03:18PM EDT  Plasma Stocks Quiet; Reuters Reports NIH Advisors Say Data Fail To Back Trump-Backed Plasma Therapy   Benzinga
07:13AM EDT  Bicycle Therapeutics Announces First Patient Dosed In Oxurion's Phase II Study Of THR-149   RTTNews
07:00AM EDT  Bicycle Therapeutics Announces First Patient Dosed In Oxurion's Phase II Trial Using Novel Bicycle-Based Plasma Kallikrein Inhibitor For Treatment Of Diabetic Macular Edema   Benzinga
06:59AM EDT  Bicycle Therapeutics Announces First Patient Dosed in Oxurion's Phase II Trial Using a Novel Bicycle(r)-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema   Business Wire
Aug 11, 2020
07:04AM EDT  Bicycle Therapeutics Appoints Dominic Smethurst As Chief Medical Officer   RTTNews
06:59AM EDT  Bicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer   Business Wire
Aug 5, 2020
04:05PM EDT  Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference   Business Wire
07:19AM EDT  Bicycle Therapeutics Q2 Loss/shr $0.67 Vs. Loss/shr $1.40 Last Year   RTTNews
07:15AM EDT  Bicycle Therapeutics Q2 EPS $(0.67) Up From $(1.40) YoY, Sales $1.57M Up From $1.52M YoY   Benzinga
06:59AM EDT  Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC